Helus Pharma reports Q3 net loss $42.7M vs. $7.5M last year

Cash totaled $195.1M as of December 31, 2025, before any adjustments for post quarter events. “The third quarter reflects continued disciplined execution across Helus Pharma’s (HELP) clinical and operational priorities,” said Michael Cola, CEO. “We are advancing a differentiated, multi-asset neuroscience portfolio with programs spanning multiple stages of development and indications. With a strong balance sheet, continued progress across our HLP003 Phase 3 and HLP004 Phase 2 programs, and a focus on scalable, repeatable clinical architectures, Helus Pharma is well positioned as we move toward upcoming clinical catalysts and long-term value creation.”